Kysenius, Kai
Paul, Bence
Hilton, James B.
Liddell, Jeffrey R.
Hare, Dominic J.
Crouch, Peter J.
Funding for this research was provided by:
National Health and Medical Research Council (GNT1122981)
Motor Neurone Disease Research Institute of Australia
Sigrid Juséliuksen Säätiö
Article History
Received: 2 July 2018
Revised: 18 August 2018
Accepted: 4 September 2018
First Online: 15 September 2018
Compliance with ethical standards
: The use of biological material taken from wild-type C57/B6 and transgenic mice was approved by The University of Melbourne Animal Ethics Committee (approval number 1312908). All procedures were conducted in accordance with National Health and Medical Research Council guidelines.
: Bence Paul receives part of his salary from the sales of the Iolite software. Dominic J Hare receives research and material support from Agilent Technologies through the National Health and Medical Research Career Development Fellowship program. Procypra Therapeutics LLC, Collaborative Medicinal Development LLC, and The University of Melbourne are engaged in development of new therapeutics for ALS using the transgenic animal described herein. The other authors declare that they have no conflict of interest.